Antimetabolite radiosensitizers.


Radiosensitization with antimetabolites has improved clinical outcome for patients with solid malignancies, especially cancers of the GI tract, cervix, and head and neck. Fluorouracil (FU) and hydroxyurea have been widely used clinically during the last four decades, and promising results have been observed more recently with gemcitabine. Although the… (More)


Cite this paper

@article{Shewach2007AntimetaboliteR, title={Antimetabolite radiosensitizers.}, author={Donna S. Shewach and Theodore Steven Lawrence}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2007}, volume={25 26}, pages={4043-50} }